vs
REGAL REXNORD CORP（RRX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
REGAL REXNORD CORP的季度营收约是Revvity的2.0倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 4.2%，领先8.6%），Revvity同比增速更快（5.9% vs 4.3%），Revvity自由现金流更多（$161.8M vs $140.6M），过去两年Revvity的营收复合增速更高（9.0% vs -0.8%）
Regal Rexnord Corporation（股票代码RRX）总部位于美国威斯康星州密尔沃基，是专业生产电动机与动力传动部件的制造商，在美国、加拿大、墨西哥、欧洲及亚洲多地设有生产、销售及服务机构，全球员工约2.9万人。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
RRX vs RVTY — 直观对比
营收规模更大
RRX
是对方的2.0倍
$772.1M
营收增速更快
RVTY
高出1.6%
4.3%
净利率更高
RVTY
高出8.6%
4.2%
自由现金流更多
RVTY
多$21.2M
$140.6M
两年增速更快
RVTY
近两年复合增速
-0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $63.4M | $98.4M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 10.8% | 14.5% |
| 净利率 | 4.2% | 12.7% |
| 营收同比 | 4.3% | 5.9% |
| 净利润同比 | 53.9% | 3.9% |
| 每股收益（稀释后） | $0.95 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RRXRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.5B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.5B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润RRXRVTY
| Q4 25 | $63.4M | $98.4M | ||
| Q3 25 | $79.6M | $46.7M | ||
| Q2 25 | $79.2M | $53.9M | ||
| Q1 25 | $57.3M | $42.2M | ||
| Q4 24 | $41.2M | $94.6M | ||
| Q3 24 | $72.7M | $94.4M | ||
| Q2 24 | $62.5M | $55.4M | ||
| Q1 24 | $19.8M | $26.0M |
毛利率RRXRVTY
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.0% | 53.6% | ||
| Q2 25 | 37.7% | 54.5% | ||
| Q1 25 | 37.2% | 56.5% | ||
| Q4 24 | 34.9% | — | ||
| Q3 24 | 37.7% | 56.3% | ||
| Q2 24 | 36.9% | 55.7% | ||
| Q1 24 | 35.7% | 54.6% |
营业利润率RRXRVTY
| Q4 25 | 10.8% | 14.5% | ||
| Q3 25 | 11.6% | 11.7% | ||
| Q2 25 | 12.2% | 12.6% | ||
| Q1 25 | 11.3% | 10.9% | ||
| Q4 24 | 8.8% | 16.3% | ||
| Q3 24 | 11.8% | 14.3% | ||
| Q2 24 | 12.5% | 12.4% | ||
| Q1 24 | 8.7% | 6.8% |
净利率RRXRVTY
| Q4 25 | 4.2% | 12.7% | ||
| Q3 25 | 5.3% | 6.7% | ||
| Q2 25 | 5.3% | 7.5% | ||
| Q1 25 | 4.0% | 6.4% | ||
| Q4 24 | 2.8% | 13.0% | ||
| Q3 24 | 4.9% | 13.8% | ||
| Q2 24 | 4.0% | 8.0% | ||
| Q1 24 | 1.3% | 4.0% |
每股收益（稀释后）RRXRVTY
| Q4 25 | $0.95 | $0.86 | ||
| Q3 25 | $1.20 | $0.40 | ||
| Q2 25 | $1.19 | $0.46 | ||
| Q1 25 | $0.86 | $0.35 | ||
| Q4 24 | $0.61 | $0.77 | ||
| Q3 24 | $1.09 | $0.77 | ||
| Q2 24 | $0.94 | $0.45 | ||
| Q1 24 | $0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $521.7M | $919.9M |
| 总债务越低越好 | $4.8B | — |
| 股东权益账面价值 | $6.8B | $7.3B |
| 总资产 | $13.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.70× | — |
8季度趋势，按日历期对齐
现金及短期投资RRXRVTY
| Q4 25 | $521.7M | $919.9M | ||
| Q3 25 | $400.0M | $931.4M | ||
| Q2 25 | $320.1M | $991.8M | ||
| Q1 25 | $305.3M | $1.1B | ||
| Q4 24 | $393.5M | $1.2B | ||
| Q3 24 | $458.6M | $1.2B | ||
| Q2 24 | $510.4M | $2.0B | ||
| Q1 24 | $465.3M | $1.7B |
总债务RRXRVTY
| Q4 25 | $4.8B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.7B | — | ||
| Q2 24 | $5.8B | — | ||
| Q1 24 | $6.2B | — |
股东权益RRXRVTY
| Q4 25 | $6.8B | $7.3B | ||
| Q3 25 | $6.8B | $7.4B | ||
| Q2 25 | $6.7B | $7.6B | ||
| Q1 25 | $6.4B | $7.6B | ||
| Q4 24 | $6.3B | $7.7B | ||
| Q3 24 | $6.5B | $7.9B | ||
| Q2 24 | $6.4B | $7.9B | ||
| Q1 24 | $6.3B | $7.8B |
总资产RRXRVTY
| Q4 25 | $13.9B | $12.2B | ||
| Q3 25 | $13.9B | $12.1B | ||
| Q2 25 | $13.9B | $12.4B | ||
| Q1 25 | $14.0B | $12.4B | ||
| Q4 24 | $14.0B | $12.4B | ||
| Q3 24 | $14.6B | $12.8B | ||
| Q2 24 | $14.6B | $13.4B | ||
| Q1 24 | $15.1B | $13.4B |
负债/权益比RRXRVTY
| Q4 25 | 0.70× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 0.91× | — | ||
| Q1 24 | 1.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $167.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $140.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 9.2% | 21.0% |
| 资本支出强度资本支出/营收 | 1.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.65× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $893.1M | $509.4M |
8季度趋势，按日历期对齐
经营现金流RRXRVTY
| Q4 25 | $167.8M | $182.0M | ||
| Q3 25 | $197.5M | $138.5M | ||
| Q2 25 | $523.2M | $134.3M | ||
| Q1 25 | $102.3M | $128.2M | ||
| Q4 24 | $213.2M | $174.2M | ||
| Q3 24 | $154.8M | $147.9M | ||
| Q2 24 | $158.3M | $158.6M | ||
| Q1 24 | $83.1M | $147.6M |
自由现金流RRXRVTY
| Q4 25 | $140.6M | $161.8M | ||
| Q3 25 | $174.0M | $120.0M | ||
| Q2 25 | $493.0M | $115.5M | ||
| Q1 25 | $85.5M | $112.2M | ||
| Q4 24 | $183.9M | $149.8M | ||
| Q3 24 | $125.5M | $125.6M | ||
| Q2 24 | $125.9M | $136.6M | ||
| Q1 24 | $64.6M | $129.7M |
自由现金流率RRXRVTY
| Q4 25 | 9.2% | 21.0% | ||
| Q3 25 | 11.6% | 17.2% | ||
| Q2 25 | 33.0% | 16.0% | ||
| Q1 25 | 6.0% | 16.9% | ||
| Q4 24 | 12.6% | 20.5% | ||
| Q3 24 | 8.5% | 18.4% | ||
| Q2 24 | 8.1% | 19.7% | ||
| Q1 24 | 4.2% | 20.0% |
资本支出强度RRXRVTY
| Q4 25 | 1.8% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 2.0% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 2.0% | 3.3% | ||
| Q2 24 | 2.1% | 3.2% | ||
| Q1 24 | 1.2% | 2.7% |
现金转化率RRXRVTY
| Q4 25 | 2.65× | 1.85× | ||
| Q3 25 | 2.48× | 2.97× | ||
| Q2 25 | 6.61× | 2.49× | ||
| Q1 25 | 1.79× | 3.03× | ||
| Q4 24 | 5.17× | 1.84× | ||
| Q3 24 | 2.13× | 1.57× | ||
| Q2 24 | 2.53× | 2.87× | ||
| Q1 24 | 4.20× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RRX
| Other | $470.6M | 31% |
| Industrial Powertrain Solutions Segment | $441.8M | 29% |
| Automation And Motion Control Segment | $327.7M | 22% |
| Power Efficiency Solutions Segment | $283.2M | 19% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
